economybharat.com

We Can Cover You
Click here
Facebook Youtube Instagram Linkedin
13
13

Eisai

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases OG_NewsReleaseCompanyLogo_92984.jpg

Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases

creativebharatgroup@gmail.com December 23, 2024
TOKYO, Japan:   Fujirebio Holdings, Inc. (President & CEO: Goki Ishikawa; Head Office:...
Read More Read more about Fujirebio and Eisai Enter into Memorandum of Understanding for Joint Research and Social Implementation of Blood-based Biomarkers in the Field of Neurodegenerative Diseases
Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion

Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion

creativebharatgroup@gmail.com November 8, 2024
Stockholm, Sweden, November 8, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B)...
Read More Read more about Eisai updates Leqembi® outlook for fiscal year 2024 (April 2024 – March 2025). Sales now expected to reach JPY 42.5 billion
Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US

creativebharatgroup@gmail.com October 31, 2024
Stockholm, Sweden November 1, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B)...
Read More Read more about Eisai completes rolling BLA submission for subcutaneous maintenance dosing of Leqembi® (lecanemab-irmb) in the US